| Previous Close | 18.78 |
| Open | 18.75 |
| Bid | 16.10 x 800 |
| Ask | 16.21 x 1000 |
| Day's Range | 16.00 - 20.20 |
| 52 Week Range | 14.80 - 25.47 |
| Volume | 70,307 |
| Avg. Volume | 67,146 |
| Market Cap | 388.066M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -98.53 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.75 |
- U.S. Food and Drug Administration (FDA) cleared TCR2's investigational new drug (IND) application for its lead solid tumor candidate TC-210; Company initiated Phase 1/2 clinical trial - Initial public ...
CAMBRIDGE, Mass. , March 28, 2019 /PRNewswire/ -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell receptor (TCR) therapies ...
CAMBRIDGE, Mass. and LONDON, March 26, 2019 /PRNewswire/ -- TCR2 Therapeutics Inc. (TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell receptor (TCR) therapies for patients suffering from cancer, today announced it has selected the advanced therapy medicinal products (ATMP) ecosystem in the United Kingdom (UK) to establish a site for global manufacturing systems and capabilities. TCR2 will work with Cell and Gene Therapy Catapult (CGT Catapult) at their Stevenage manufacturing center to produce its novel TCR therapies based on the company's proprietary TRuC™ (TCR Fusion Construct) T cells.
CAMBRIDGE, Mass., Feb. 26, 2019 /PRNewswire/ -- TCR2 Therapeutics Inc. (TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell receptor (TCR) therapies for patients suffering from cancer, today announced that the underwriters of its recent initial public offering of common stock have exercised in full their over-allotment option and purchased an additional 750,000 shares at $15.00 per share, before deducting underwriting discounts and commissions. On February 13, 2019, TCR2 priced its initial public offering of 5,000,000 shares of common stock at $15.00 per share.
CAMBRIDGE, Mass. , Feb. 13, 2019 /PRNewswire/ -- TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell receptor (TCR) therapies for ...
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates below are expected but not confirmed. Anchiano Therapeutics Ltd. (ANCN) will issue 2.4 million shares at $14.55 ...